🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

SMS Pharmaceuticals Limited SMSPHARMA NSEPHARMA

Healthcare · Drug Manufacturers - General · India
https://smspharma.com
Company Profile ↓
₹401.40
+69.99% 1Y
Mkt Cap₹3,759.19 Cr
P/E49.19
P/B4.76
Div. Yield0.10%
52W High₹438.30
52W Low₹214.42
Book Value₹83.91
EPS (TTM)₹8.16

Company Overview

SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyderabad, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 514.9% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 19.5% CAGR over the past five years.

Recent Developments

  • Mar 2026 Revenue of ₹886.87 Cr (+13.3% YoY); net profit ₹101.99 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +13.3%, earnings +47.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 19.5%, profit CAGR 514.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:19.50%
1 Year:13.30%

Compounded Profit Growth

5 Years:514.92%
1 Year:47.52%

Stock Price Performance

1 Year:+69.99%
6 Months:+16.89%
3 Months:-8.42%
1 Month:+6.19%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 84% of range
₹214.42 ₹438.30
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)53.27 · Neutral
Price Performance
1M+6.19%
3M-8.42%
6M+16.89%
1Y+69.99%
Valuation vs Sector

P/E of 49.19 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 19.5% over 5 years.
  • Profit CAGR of 514.9% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
49.19
Industry PE
39.97
Forward P/E est.
33.34
PEG Ratio
0.94
Book Value
₹83.91
Price to Book
4.76
P/S
4.22
EV/EBITDA
23.19
Dividend Yield
0.10%

Growth (CAGR)

Revenue 5Y
19.50%
Profit 5Y
514.92%
Revenue (YoY)
13.30%
Earnings (YoY)
47.52%

Profitability & Returns

ROCE
13.84%
ROE
12.98%
ROA
7.49%
Profit Margin
11.50%
Op Margin
14.81%
Gross Margin
34.15%
EPS (Latest Qtr)
₹3.58
EPS (TTM)
₹8.16

Balance Sheet & Liquidity

Debt/Equity
0.46
Quick Ratio
0.81
Current Ratio
1.81
Debt
₹365.05 Cr
Total Assets
₹1,362.44 Cr
Current Assets
₹638.01 Cr
Working Capital
₹285.03 Cr

Ownership

Promoter Holding
74.52%
Chg in Prom Hold
-1.03%
FII / Inst Holding
2.99%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
₹3,759.19 Cr
Total Revenue (TTM)
₹886.87 Cr
EBITDA
₹179.63 Cr
Free Cash Flow
₹-71.33 Cr
Operating Cash Flow
₹59.22 Cr
Shares Outstanding
₹9.37 Cr
Gross Margin
34.15%
Payout Ratio
3.59%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SMSPHARMA SMS Pharmaceuticals Limited NSEPHARMA 401.40 49.19 ₹3,759.19 Cr 0.10% 13.84% 12.98% 19.50% 514.92%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 149.00 Cr135.00 Cr167.00 Cr161.00 Cr246.00 Cr164.00 Cr--248.20 Cr196.05 Cr242.43 Cr210.45 Cr237.95 Cr
Cost of Revenue --------171.74 Cr130.70 Cr165.56 Cr135.56 Cr156.66 Cr
Gross Profit --------76.45 Cr65.35 Cr76.87 Cr74.89 Cr81.28 Cr
Operating Expenses 126.00 Cr109.00 Cr139.00 Cr132.00 Cr212.00 Cr131.00 Cr--44.29 Cr35.73 Cr38.52 Cr41.26 Cr51.51 Cr
Operating Income 15.00 Cr18.00 Cr20.00 Cr21.00 Cr26.00 Cr26.00 Cr--32.17 Cr29.62 Cr38.34 Cr33.63 Cr29.77 Cr
EBITDA 23.00 Cr26.00 Cr28.00 Cr29.00 Cr34.00 Cr34.00 Cr--42.23 Cr39.96 Cr49.80 Cr47.40 Cr42.47 Cr
Interest Expense 6.00 Cr6.00 Cr6.00 Cr6.00 Cr6.00 Cr5.00 Cr--5.07 Cr5.84 Cr5.74 Cr6.22 Cr5.28 Cr
Pretax Income 11.00 Cr13.00 Cr15.00 Cr17.00 Cr22.00 Cr22.00 Cr--28.52 Cr24.37 Cr34.04 Cr31.16 Cr27.07 Cr
Tax Provision 2.64 Cr4.03 Cr3.15 Cr4.42 Cr5.72 Cr5.50 Cr--8.44 Cr5.65 Cr8.91 Cr7.97 Cr6.10 Cr
Net Income 6.00 Cr9.00 Cr12.00 Cr11.00 Cr17.00 Cr16.00 Cr--20.31 Cr20.49 Cr25.31 Cr23.47 Cr32.71 Cr
Diluted EPS 0.731.101.381.362.041.95--2.402.312.842.593.58

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 193.00 Cr611.00 Cr438.00 Cr463.00 Cr465.00 Cr412.00 Cr563.00 Cr-519.75 Cr706.46 Cr782.75 Cr886.87 Cr
Cost of Revenue --------390.61 Cr497.71 Cr518.05 Cr584.05 Cr
Gross Profit --------129.14 Cr208.75 Cr264.70 Cr302.83 Cr
Operating Expenses 145.00 Cr522.00 Cr363.00 Cr369.00 Cr375.00 Cr332.00 Cr442.00 Cr-106.66 Cr123.50 Cr160.04 Cr171.47 Cr
Operating Income 42.00 Cr70.00 Cr56.00 Cr73.00 Cr71.00 Cr58.00 Cr99.00 Cr-22.48 Cr85.25 Cr104.65 Cr131.36 Cr
EBITDA 47.00 Cr89.00 Cr75.00 Cr93.00 Cr90.00 Cr80.00 Cr121.00 Cr-58.47 Cr120.24 Cr145.22 Cr179.63 Cr
Interest Expense 8.00 Cr17.00 Cr16.00 Cr15.00 Cr12.00 Cr12.00 Cr11.00 Cr-20.99 Cr22.62 Cr18.54 Cr23.08 Cr
Pretax Income 40.00 Cr56.00 Cr42.00 Cr60.00 Cr62.00 Cr51.00 Cr91.00 Cr-5.35 Cr66.11 Cr92.34 Cr116.64 Cr
Tax Provision 14.40 Cr14.56 Cr5.88 Cr19.80 Cr21.08 Cr18.36 Cr30.03 Cr-1.47 Cr16.91 Cr24.94 Cr28.64 Cr
Net Income 25.00 Cr41.00 Cr28.00 Cr32.00 Cr40.00 Cr32.00 Cr63.00 Cr--7.06 Cr49.83 Cr69.14 Cr101.99 Cr
Diluted EPS 2.554.833.363.754.733.737.387.35-0.835.898.16-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 329.00 Cr656.00 Cr493.00 Cr503.00 Cr559.00 Cr608.00 Cr812.00 Cr-879.61 Cr1,034.09 Cr1,152.68 Cr1,362.44 Cr
Current Assets --------410.65 Cr533.89 Cr554.47 Cr638.01 Cr
Cash & Equivalents --------7.31 Cr36.04 Cr41.40 Cr45.88 Cr
Inventory --------223.50 Cr233.70 Cr284.73 Cr351.21 Cr
Receivables --------148.35 Cr236.23 Cr203.23 Cr215.87 Cr
Total Liabilities --------419.08 Cr497.76 Cr513.04 Cr576.63 Cr
Current Liabilities --------254.91 Cr331.72 Cr324.37 Cr352.98 Cr
Long Term Debt --------121.13 Cr122.09 Cr139.36 Cr171.64 Cr
Total Debt 73.00 Cr204.00 Cr149.00 Cr146.00 Cr144.00 Cr157.00 Cr255.00 Cr-254.07 Cr280.77 Cr310.76 Cr365.05 Cr
Total Equity 192.00 Cr293.00 Cr254.00 Cr284.00 Cr321.00 Cr348.00 Cr410.00 Cr-460.53 Cr536.33 Cr639.64 Cr785.81 Cr
Shares Outstanding --------8.47 Cr8.47 Cr8.87 Cr9.37 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 14.00 Cr61.00 Cr73.00 Cr32.00 Cr50.00 Cr40.00 Cr90.00 Cr-22.45 Cr50.12 Cr81.71 Cr59.22 Cr
Investing Cash Flow -32.00 Cr-97.00 Cr-39.00 Cr-17.00 Cr-35.00 Cr-43.00 Cr-152.00 Cr--29.76 Cr-52.07 Cr-123.43 Cr-130.78 Cr
Financing Cash Flow 107.00 Cr27.00 Cr-33.00 Cr-15.00 Cr-13.00 Cr-2.00 Cr92.00 Cr--31.97 Cr30.68 Cr47.08 Cr76.03 Cr
Capital Expenditure -19.00 Cr-88.00 Cr-23.00 Cr-9.00 Cr-35.00 Cr-43.00 Cr-151.00 Cr--29.92 Cr-52.16 Cr-123.38 Cr-130.56 Cr
Free Cash Flow -5.00 Cr-27.00 Cr50.00 Cr23.00 Cr15.00 Cr-3.00 Cr-61.00 Cr--7.47 Cr-2.04 Cr-41.67 Cr-71.33 Cr
Net Change in Cash 89.00 Cr-9.00 Cr1.00 Cr02.00 Cr-5.00 Cr31.00 Cr--39.27 Cr28.73 Cr5.36 Cr4.48 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------24.8%29.5%33.8%34.1%
Operating Margin % 21.8%11.5%12.8%15.8%15.3%14.1%17.6%-4.3%12.1%13.4%14.8%
Net Margin % 13.0%6.7%6.4%6.9%8.6%7.8%11.2%--1.4%7.1%8.8%11.5%
ROE % 13.0%14.0%11.0%11.3%12.5%9.2%15.4%--1.5%9.3%10.8%13.0%
ROCE % --------3.6%12.1%12.6%13.0%

Shareholding Pattern

Insiders
74.52%
Institutions
2.99%
Public Float
11.73%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SMSPHARMA

Google News Sun, 31 May 2026

SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxNNVp1SG04R2JqS2FGTFpSNFFTOWR5R29tUDBiSFR5Y1BBdVd0VnVUVy1PakE4VmZDd3JZa3hHay0wX2xORzJRTVk4M3BNT2ZwUlJsUzBpVUNMV1oyWTZ5QVZFM0EwQ29oNGx1WEtGZHVpRmpwR21OejJLb05uWVNMYWdyWlBkeEtXN1gteV…

Google News Sat, 06 Jun 2026

Fraudsters Used Fake Documents to Sell SMS Pharma Shares Worth Rs 3.31 Crore, Probe On - Medical Dialogues

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQVHhkUGhTWU8wQUlQeV8xbG5pdm1pUnJxUUh5RjhBM1lGNmRhVlpsbzFyNGIzd3E1clFtVGRaM1NTQ21CM2g3MURaeVVMS1lOV0VRS0NyYjBwY1FIWVB4a2FtREVEbkdjcWk0Wi1JblV1TEhiam93cnJGRWswNy1VemhndnBkc0t5Q1BLdX…

Google News Wed, 26 Nov 2025

SMS Pharma up 8% as arm gets USFDA nod for reformulated Ranitidine tablets - Business Standard

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNeVk5Z2ltRUQwR3AxSWpWai1xbEVMTE5makdqMWFFU20xNVpYakxYVG9IbG44bTFXMEc2TWFHNDVqV2hxbE5ZOWEzdmlnMjJUWk9BNU9mM3BiOXdYYURsemcwT1VnbE9WQ0hjdHVSNmljQ3NmenRZU0Z3bUliOGFydGY0dVM4OW1HSDNWeG…

Google News Mon, 10 Nov 2025

SMS Pharma Shares Surge 12% on 74% Profit Jump in Q2FY26 - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNenk3cV9UUGZKSjN3NkMyQVIyWkwtR2pRYm8tcXJmaGhXUUo2T2tqd2lMcVZ4OEdQeWplbWVXd0pvLUVmNU11LVZnSG1fdlctcEttVlZGYjZONnhrRkFLZnNreFY1YWh4UTBTWlZXU2Y0REJlSTVYYkpYN3Vzclh0Y2gzUFJuSkM0ZVJPSG…

Google News Sat, 03 Jan 2026

SMS Pharmaceuticals Ltd. Share Price Today - SMS Pharmaceuticals Ltd. Stock Price Live NSE/BSE - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxNMFNFZ0g2SzltV0tZMmk4M1lhajBJMmxYMXJYLUNqU3laN2pCazU0Qi1DWDB2RTFKU0JKNV9LNTFHa1VfWkxmMjRuNTN5RTV5UDF3RXhla2Nuc0ZWdXgtanBjdmxqeVRJQ3BMcnREcEpPOXlZV3d0UVF2UlF4SXFTbmtObmUzZDA?oc=5" …

Google News Wed, 26 Jul 2017

SMSPHARMA Stock Price and Chart — NSE:SMSPHARMA - TradingView

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1ReVhlUHBLN2laSGljamp1SzIxZXpZbjhPOGZTWFFsTnRsQnVMUk9mVm11NHh5OXFMcnl2YXFyRUNjQ0gxZXBDVlhvNVRNQUpsc3BFcEw0dEdxQXlObkE4?oc=5" target="_blank">SMSPHARMA Stock Price and Chart — NSE:S…

SMSPHARMA — Frequently Asked Questions

What is the current share price of SMS Pharmaceuticals Limited (SMSPHARMA)?

As of 2026-07-15 09:52 IST, SMS Pharmaceuticals Limited (SMSPHARMA) trades at ₹401.40 on NSE. Its 52-week range is ₹214.42 to ₹438.30.

What is the market capitalisation of SMSPHARMA?

SMS Pharmaceuticals Limited (SMSPHARMA) has a market capitalisation of ₹3,759.19 Cr on NSE.

What is the P/E ratio of SMSPHARMA?

SMSPHARMA trades at a trailing price-to-earnings (P/E) ratio of 49.19. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 4.76.

Does SMSPHARMA pay a dividend?

SMS Pharmaceuticals Limited (SMSPHARMA) currently offers a dividend yield of 0.10%.

What is the return on equity (ROE) of SMSPHARMA?

SMSPHARMA has a return on equity (ROE) of 12.98%. Its return on capital employed (ROCE) is 13.84%.

Is SMSPHARMA a good stock to buy?

This page provides a data-driven analysis of SMS Pharmaceuticals Limited (SMSPHARMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space